The global humanized mice model market reached USD 155 million in 2025 and is set to reach USD 298.5 million by 2034, a compound annual growth rate of 7.14%; the market first crosses USD 172 million in 2026. Contrive Datum Insights lays out that trajectory year by year in its report on the humanized mice model market.
A humanized mouse or rat model is a laboratory animal built to carry components of a human immune system: human hematopoietic stem cells, peripheral blood mononuclear cells, or specific human genes inserted through genetic engineering. Its biological responses mirror a human patient's more closely than an unmodified rodent's, which lets researchers watch how a disease, a pathogen or a candidate drug interacts with a human-like immune system before the drug reaches a person. Three groups buy these models: pharmaceutical and biotechnology companies developing oncology and immunology therapies, contract research organizations running preclinical studies for outside drug sponsors, and academic and government institutions studying immune biology and infectious disease.
Growth over the forecast period traces mostly to one cause: wider use of humanized mouse and rat models inside immuno-oncology drug development, an impact the study rates high. That driver is why the rat-model line outpaces the market overall while the mouse-model line, still the larger of the two, grows closer to the market's own rate.
Humanized Mouse Models supplied 88% of 2025 revenue, USD 136.4 million, holding 82% by 2034 while compounding at 6.3% a year. Humanized Rat Models started at 12% of 2025 revenue and grows at 11.93%, lifting its share to 18% and its value from USD 18.6 million to USD 53.7 million. Pharmaceutical and biotechnology companies accounted for 52% of 2025 revenue (USD 80.6 million), though contract research organizations expand fastest, at 9.24%. PBMC humanization led the technology split in 2025 at 45% (USD 69.8 million); genetically engineered knock-in humanization grows quickest, at 10.71%. Oncology and immuno-oncology research drove 46% of 2025 revenue (USD 71.3 million), and infectious disease research grows fastest, at 9.98%. Off-the-shelf catalog models supplied 58% of 2025 revenue (USD 89.9 million); custom model development services expand fastest, at 10.08%.
North America is the largest region, holding 45% of 2025 revenue (USD 69.7 million) and climbing to USD 119.4 million by 2034. Asia Pacific's share rises over the same period, from 22% (USD 34.1 million) to 29% (USD 86.6 million). Middle East and Africa stays the smallest region throughout, moving from 3.5% of 2025 revenue to 4% by 2034. Within North America, the United States alone accounts for USD 61.3 million in 2025, 39.5% of the global total.
The USD 298.5 million forecast for 2034 sits between two named scenarios. A faster path, USD 340.3 million, would need contract research organizations adopting humanized models sooner and Asia Pacific converting more of its current immuno-oncology pipeline into funded preclinical work. A slower path, USD 262.7 million, follows if biotechnology funding tightens and early-stage immuno-oncology and cell therapy programs take longer to reach funded preclinical studies across every region; that delay, more than any single competitive shift, would pull the market off its base-case path.